Skip to main content

Research Repository

Advanced Search

American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Dowsett, Mitch; Goldstein, Neil S.; Hicks, David G.; Mangu, Pamela B.; Osborne, C. Kent; Sweep, Fred C.G.; Wittliff, James L.; Dowsett, Mitchell; Hammond, M. Elizabeth H.; Hayes, Daniel F.; Allred, D. Craig; Hagerty, Karen L.; Badve, Sunil; Fitzgibbons, Patrick L.; McShane, Lisa M.; Francis, Glenn; Hayes, Malcolm; Lester, Susan; Love, Richard; Sweep, Fred CG; Miller, Keith; Paik, Soonmyung; Perlmutter, Jane; Rhodes, Anthony; Sasano, Hironobu; Schwartz, Jared N.; Taube, Sheila; Torlakovic, Emina Emilia; Valenstein, Paul; Viale, Giuseppe; Visscher, Daniel; Wheeler, Thomas; Williams, R. Bruce; Wolff, Antonio C.

Authors

Mitch Dowsett

Neil S. Goldstein

David G. Hicks

Pamela B. Mangu

C. Kent Osborne

Fred C.G. Sweep

James L. Wittliff

Mitchell Dowsett

M. Elizabeth H. Hammond

Daniel F. Hayes

D. Craig Allred

Karen L. Hagerty

Sunil Badve

Patrick L. Fitzgibbons

Lisa M. McShane

Glenn Francis

Malcolm Hayes

Susan Lester

Richard Love

Fred CG Sweep

Keith Miller

Soonmyung Paik

Jane Perlmutter

Anthony Rhodes

Hironobu Sasano

Jared N. Schwartz

Sheila Taube

Emina Emilia Torlakovic

Paul Valenstein

Giuseppe Viale

Daniel Visscher

Thomas Wheeler

R. Bruce Williams

Antonio C. Wolff



Abstract

Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers. Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance. Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria. Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials. © 2010 by American Society of Clinical Oncology and College of American Pathologists.

Citation

Wittliff, J. L., Sweep, F. C., Osborne, C. K., Mangu, P. B., Hicks, D. G., Goldstein, N. S., …Wolff, A. C. (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology, 28(16), 2784-2795. https://doi.org/10.1200/JCO.2009.25.6529

Journal Article Type Review
Publication Date Jun 1, 2010
Deposit Date Jan 26, 2011
Journal Journal of Clinical Oncology
Print ISSN 0732-183X
Electronic ISSN 1527-7755
Publisher American Society of Clinical Oncology
Peer Reviewed Peer Reviewed
Volume 28
Issue 16
Pages 2784-2795
DOI https://doi.org/10.1200/JCO.2009.25.6529
Keywords breast cancer, immunohistochemical testing
Public URL https://uwe-repository.worktribe.com/output/978254
Publisher URL http://dx.doi.org/10.1200/JCO.2009.25.6529




Downloadable Citations